REGENXBIO Inc

RGNXNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

54.2M

on 2026-06-30, from 49.0M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$300.0M

S-3 of 2025-11-26. 1 prospectus supplement filed under it since. S-3 ↗

$150.0M

Leerink Partners, agreement of 2024-12-09. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

1.7 quarters

$105.5M on 2026-06-30 ÷ $61.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-07-16	Public offering	10,003,889	$9.00	$100.0M	424B5 ↗